- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00305175
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
The primary objectives of this prospective, observational study are (1) to describe the long-term cellular, molecular, and clinical effects of hydroxyurea therapy in sickle cell disease, and (2) to perform hydroxyurea pharmacokinetics studies.
This study will follow sickle cell patients being treated with hydroxyurea for a long period of time to evaluate the long-term cellular and molecular effects of the drug on the patients' body. This study will consist of two patient groups. One group will be made up of patients who have received hydroxyurea therapy before entering the study. The second group will be made up of patients who have not received hydroxyurea before study entry.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Many years of study have documented the severe effects of sickle cell disease. Some of these effects include hemolysis (the break down of red blood cells), blockages in the blood vessels, and damage to the organs systems of the body. Hydroxyurea, which is given by mouth, is used to effectively prevent blockages in the blood vessels of patients with sickle cell disease. The hydroxyurea dosage varies and the responses of the body to this drug are not well understood.
This study will follow sickle cell patients being treated with hydroxyurea for a long period of time to evaluate the long-term cellular and molecular effects of the drug on the patients' body. This study will consist of two patient groups. One group will be made up of patients who have received hydroxyurea therapy before entering the study (Old Cohort). The second group will be made up of patients who have not received hydroxyurea before study entry (New Cohort).
This is not a therapeutic drug trial. Subjects for this study will receive hydroxyurea therapy for accepted clinical indications, and will be treated per best clinical management using treatment algorithms established at St. Jude Children's Research Hospital and other pediatric sickle cell programs across the United States. Hydroxyurea therapy data (such as dosing and duration of therapy) will not be dictated by this study, but will be collected to correlate with long-term outcomes. Hydroxyurea dose escalation to a stable MTD will occur according to published guidelines.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38105
- St. Jude Children's Research Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Patients from birth up to age 30 years
- Diagnosis of sickle cell disease
- Patients who are receiving hydroxyurea therapy or plan to begin hydroxyurea therapy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
---|
Patients With Prior Hydroxyurea
Patients who have received hydroxyurea therapy before entering the study.
|
Patients Without Prior Hydroxyurea
Patients who have not received hydroxyurea before study entry.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
DNA damage from hydroxyurea therapy-variable-diversity-joining (VDJ) recombination events defined as the number of events per microgram of genomic DNA;
Tijdsspanne: Every 3 years
|
Every 3 years
|
DNA damage from hydroxyurea therapy-percentage of HJB in immature (CD71+) erythrocytes
Tijdsspanne: Every 3 years
|
Every 3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Brain function as measured by MRI/MRA and TCD
Tijdsspanne: Every 3 years
|
optional test
|
Every 3 years
|
Splenic function as measured by Spleen Scan
Tijdsspanne: Every 3 years
|
optional test
|
Every 3 years
|
Kidney function as measured by BUN/creatinine and Urinalysis, glomerular filtration rate (GFR)
Tijdsspanne: Every 3 years
|
optional test
|
Every 3 years
|
Lung function as measured by forced vital capacity (FVC) (%), forced vital volume in 1 second (FVC1) (%), and tricuspid regurgitation (TR) jet on Echocardiogram (ECHO)
Tijdsspanne: Every 3 years
|
collected if performed for clinical purposes
|
Every 3 years
|
Growth as measured by height and weight
Tijdsspanne: Every visit
|
Every visit
|
Medewerkers en onderzoekers
Medewerkers
Publicaties en nuttige links
Algemene publicaties
- Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013 Feb;88(2):116-9. doi: 10.1002/ajh.23365. Epub 2012 Dec 17.
- Flanagan JM, Steward S, Howard TA, Mortier NA, Kimble AC, Aygun B, Hankins JS, Neale GA, Ware RE. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol. 2012 Apr;157(2):240-8. doi: 10.1111/j.1365-2141.2012.09061.x. Epub 2012 Feb 24.
- Walker AL, Steward S, Howard TA, Mortier N, Smeltzer M, Wang YD, Ware RE. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. Blood. 2011 Nov 17;118(20):5664-70. doi: 10.1182/blood-2011-07-368746. Epub 2011 Sep 14.
- Flanagan JM, Howard TA, Mortier N, Avlasevich SL, Smeltzer MP, Wu S, Dertinger SD, Ware RE. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res. 2010 Apr 30;698(1-2):38-42. doi: 10.1016/j.mrgentox.2010.03.001. Epub 2010 Mar 15.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HUSTLE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Sikkelcelziekte
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
-
ExelixisVoltooidNiercelcarcinoom | Papillaire schildklierkanker | Folliculaire schildklierkanker | Huerthle Cell-schildklierkankerVerenigde Staten
-
Jeadran N. Malagón-RojasNog niet aan het wervenStress, psychisch | Ongerustheid | Blootstelling aan het milieu | Cortisol-overschot | Epigenetische stoornis | Natural Killer Cell Cytokine-productieColombia
-
National Institute of Diabetes and Digestive and...VoltooidPapillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkanker | Kwaadaardige Struma OvariiVerenigde Staten